Dr. Reddy's Laboratories/$RDY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Primary listing
NYSE
Employees
27,811
Headquarters
Hyderabad, India
Website
RDY Metrics
BasicAdvanced
$11B
17.00
$0.79
0.33
$0.07
0.53%
Price and volume
Market cap
$11B
Beta
0.33
52-week high
$16.17
52-week low
$12.26
Average daily volume
1.2M
Dividend rate
$0.07
Financial strength
Current ratio
1.852
Quick ratio
1.129
Long term debt to equity
3.214
Total debt to equity
16.167
Dividend payout ratio (TTM)
11.36%
Interest coverage (TTM)
22.06%
Profitability
EBITDA (TTM)
994.273
Gross margin (TTM)
56.43%
Net profit margin (TTM)
17.13%
Operating margin (TTM)
20.70%
Effective tax rate (TTM)
23.52%
Revenue per employee (TTM)
$138,620
Management effectiveness
Return on assets (TTM)
8.73%
Return on equity (TTM)
17.36%
Valuation
Price to earnings (TTM)
17.001
Price to revenue (TTM)
2.909
Price to book
2.8
Price to tangible book (TTM)
4.09
Price to free cash flow (TTM)
52.321
Free cash flow yield (TTM)
1.91%
Free cash flow per share (TTM)
0.257
Dividend yield (TTM)
0.53%
Forward dividend yield
0.53%
Growth
Revenue change (TTM)
14.10%
Earnings per share change (TTM)
9.95%
3-year revenue growth (CAGR)
15.38%
10-year revenue growth (CAGR)
8.27%
3-year earnings per share growth (CAGR)
23.64%
10-year earnings per share growth (CAGR)
9.43%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Bulls say / Bears say
Plans to launch a generic version of semaglutide in 87 countries position Dr. Reddy’s to capture share of the rapidly growing $150 billion obesity drug market; regulatory filings have been submitted for launch beginning 2026 in core markets such as Canada, India, Brazil, and Turkey (Reuters).
European revenues more than doubled year-on-year in Q2 FY25, driven by robust demand for the Nicotine Replacement Therapy portfolio acquired from Haleon, diversifying Dr. Reddy’s reliance away from North America (Reuters).
Supportive U.S. regulatory developments—where the FDA plans to streamline biosimilar approvals—could lower development costs and accelerate market entry for Dr. Reddy’s biosimilar candidates such as Rituximab and Denosumab (Reuters).
North American revenues fell 11.3% year-on-year in Q2 FY25 due to aggressive price erosion in key products like Lenalidomide, underscoring vulnerability in its largest market (Reuters).
Q2 FY25 net profit of ₹14.18 billion narrowly missed analyst estimates of ₹14.94 billion, reflecting margin pressure from intense competition in the generics space (Reuters).
The upcoming 2026 patent expiry of Revlimid is expected to intensify competition for Dr. Reddy’s lenalidomide generics, posing downside risks to future North America sales volumes and pricing (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dr. Reddy's Laboratories stock?
Dr. Reddy's Laboratories (RDY) has a market cap of $11B as of November 07, 2025.
What is the P/E ratio for Dr. Reddy's Laboratories stock?
The price to earnings (P/E) ratio for Dr. Reddy's Laboratories (RDY) stock is 17 as of November 07, 2025.
Does Dr. Reddy's Laboratories stock pay dividends?
Yes, the Dr. Reddy's Laboratories (RDY) stock pays dividends to shareholders. As of November 07, 2025, the dividend rate is $0.07149 and the yield is 0.53%. Dr. Reddy's Laboratories has a payout ratio of 11.36% on a trailing twelve-month basis.
When is the next Dr. Reddy's Laboratories dividend payment date?
The next Dr. Reddy's Laboratories (RDY) dividend payment date is unconfirmed.
What is the beta indicator for Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.